IDSA: New Treatment Offers Promise for Complicated UTIs

Share this content:
IDSA: New Treatment Offers Promise for Complicated UTIs
IDSA: New Treatment Offers Promise for Complicated UTIs

TUESDAY, Nov. 1, 2016 (HealthDay News) -- For the treatment of adults with complicated urinary tract infections (cUTIs), a combination of meropenem-vaborbactam (M-V) is non-inferior to piperacillin-tazobactam (P-T), according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 26 to 30 in New Orleans.

Jeff Loutit, M.B.Ch.B., of The Medicines Company in San Diego, and colleagues randomized patients to M-V or P-T for 10 days of total therapy. After 15 doses (five days) of intravenous (IV) therapy, patients could be switched to oral levofloxacin if they met prespecified criteria. For inclusion in the study, patients had to have a cUTI or acute pyelonephritis, require IV study antibiotics, and be sick enough to require at least five days of IV therapy.

Overall, success was observed in 98.4 percent of patients receiving M-V and 94.0 percent receiving P-T. Consistent efficacy was also observed for secondary end points and sub-populations. The investigators found that 37 percent of patients had treatment emergent adverse events (TEAEs), 14 percent with drug-related TEAEs, 3.9 percent with discontinuation of study drug due to AEs, and 4.2 percent with serious AEs; 0.7 percent of study participants died. Safety was similar between the groups.

"We improved upon meropenem by adding vaborbactam, a new cyclic boronic acid beta-lactamase inhibitor, which has activity against serine carbapenemases. The focus of our research efforts is to provide a new agent for the treatment of carbapenem-resistant Enterobacteriaceae (CRE)," Loutit told Physician's Briefing. "We are excited about the results of this trial as we believe M-V has the potential to be an important new drug in the treatment of patients with serious infections due to resistant organisms such as CRE."

All authors are employees of The Medicines Company, which manufactures meropenem-vaborbactam and funded the study.

Abstract No. LB-7

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »